iCell Neurons Enable Alzheimer's Disease Modeling and Demonstrate Potential Use in High Throughput Screening at GlaxoSmithKline
MADISON, Wis., Dec. 12, 2012 /PRNewswire/ -- Cellular Dynamics International (CDI), a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells, today announced the publication of research demonstrating the use of human iPSC-derived iCell® Neurons to model Alzheimer's disease (AD) and how they may be used in high throughput drug screening. This research was performed by the lab of Zhong Zhong, Ph.D., head of discovery in the regenerative medicine group within GlaxoSmithKline (GSK), and recently published online in Stem Cell Research (DOI 10.1016/j.scr.2012.11.005).
The GSK researchers used CDI's commercially available iCell Neurons, comprised of human neurons with characteristic forebrain markers, to model neuronal loss in human AD brains by exposing them to beta-amyloid 1-42 (AB1-42), a peptide known to be associated with AD. AB1-42 builds up in the brains of those susceptible to the disease and acts as a plaque that causes progressive memory loss and cognitive decline. Because iCell Neurons meet tight quality standards and are available commercially in large quantities, the researchers used this AD cellular model to screen hundreds of compounds and ultimately identified several small molecules that inhibited the AB1-42 toxicity.
This is the first known use of human iPSCs to model Alzheimer's disease through AB1-42 toxicity in a drug screen and demonstrates the value of commercial-scale quantities of human iPSC-derived cells for use in disease modeling, drug discovery, and target validation.
"Prior to iCell Neurons, the research models available to study AD included mice, human postmortem tissues, and immortalized neuronal cell lines. These models all have severe physiologic and genetic limitations," said Emile Nuwaysir, chief operating officer of CDI and co-author on the paper. "To make rapid progress in AD research, it is critical to have a cellular model that accurately recapitulates normal and disease pathology. We were excited to work with a team as talented as Dr. Zhong's to perform this study, which demonstrated that when you have a physiologically relevant and reproducible system like iCell Neurons as the basis for your screening platform, you can make rapid and dramatic discoveries."
Robert Palay, chief executive officer of CDI, added, "CDI's iCell Neurons exhibit true functional human biology. This study demonstrated the potential of high throughput screening on iCell Neurons in identifying novel therapeutic compounds. The work contained in this paper is just another example confirming that CDI's ability to supply our customers with fully functional, standardized human cells enables pharmaceutical scientists to quickly discover new drug candidates, particularly for challenging pathologies such as neurodegenerative diseases."
About Cellular Dynamics International,
Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual's stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.
SOURCE Cellular Dynamics International
CONTACT: Cellular Dynamics International, Joleen Rau, Senior Director, Marketing & Communications, Cellular Dynamics International, Inc., +1-608-310-5142, email@example.com; Robert E. Flamm, Ph.D., Russo Partners LLC, +1-212-845-4226, firstname.lastname@example.org
Web Site: http://www.cellulardynamics.com
Posted: December 2012
Recommended for you